Fulcrum’s Sickle Cell Disease Program Is Back in Business After FDA Lifts 6-Month Hold

After a six-month wait, Fulcrum Therapeutics’ sickle cell disease plans are back on track after the FDA lifted a hold on the biotech’s candidate. The regulator instigated the full clinical hold on the therapy, dubbed FDX-6058, back in February.